Literature DB >> 9177833

Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats.

J Capala1, R F Barth, M Q Bailey, R A Fenstermaker, M J Marek, B A Rhodes.   

Abstract

High grade gliomas may have amplified expression of the epidermal growth factor receptor (EGFR) gene c-erb-B, which often is associated with increased expression of transmembrane EGFR. The purpose of the present study was to develop a method for labeling EGF with 99mTc and to determine whether the resulting radioligand would localize, following intracerebral injection, in rats bearing EGFR-positive gliomas. EGF has a relatively low molecular mass (approximately 6 kDa) compared to monoclonal antibodies, and this has allowed smaller bioconjugates, which should diffuse more rapidly within the brain and more effectively target disseminated glioma cells, to be constructed. In the present study, EGF has been labeled with either 131I or 99mTc, and in vitro uptake of the resulting radioligand has been investigated using C6EGFR rat glioma cells, which had been transfected with the EGFR gene. Cellular uptake of 131I radioactivity peaked after approximately 30 min of incubation with [131I]EGF, following which time it declined, while 99mTc radioactivity continued to increase over a 6 h incubation with [99mTc]-EGF. To determine if radiolabeled EGF had in vivo tumor-localizing properties, C6EGFR glioma cells were implanted stereotactically into the brains of Fischer rats. Four weeks later, either 99mTc- or 131I-labeled EGF was injected intracerebrally into normal or glioma-bearing animals using the same stereotactic coordinates. External gamma scintigraphy revealed that 131I radioactivity disappeared rapidly from the brain regions of tumor-bearing animals compared to 99mTc, approximately 50% of which remained in the tumor for up to 12 h. In contrast, only approximately 20% remained in the brains of non-tumor-bearing animals after 6 h. These studies are the first to describe a method for radiolabeling EGF with 99mTc and to detect it by external scintigraphy in the brains of tumor-bearing animals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177833     DOI: 10.1021/bc970031s

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

1.  Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.

Authors:  W Yang; R F Barth; R Leveille; D M Adams; M Ciesielski; R A Fenstermaker; J Capala
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

Review 2.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

3.  PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model.

Authors:  Weihua Li; Gang Niu; Lixin Lang; Ning Guo; Ying Ma; Dale O Kiesewetter; Joseph M Backer; Baozhong Shen; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-23       Impact factor: 9.236

4.  Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier.

Authors:  Kiran Ramanlal Chaudhari; Mukesh Ukawala; Arehalli S Manjappa; Abhinesh Kumar; Piyush Kishor Mundada; Anil Kumar Mishra; Rashi Mathur; Jukka Mönkkönen; Rayasa S Ramchandra Murthy
Journal:  Pharm Res       Date:  2011-07-09       Impact factor: 4.200

5.  Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent.

Authors:  Datta E Ponde; ZiFen Su; Alan Berezov; Hongtao Zhang; Abbas Alavi; Mark I Greene; Ramachandran Murali
Journal:  Bioorg Med Chem Lett       Date:  2011-02-15       Impact factor: 2.823

6.  Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.

Authors:  Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

7.  Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies.

Authors:  Gitanjali Sharma; Anil Kumar Mishra; Pushpa Mishra; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2009-11-06       Impact factor: 3.246

8.  EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination?

Authors:  Robert A Fenstermaker; Michael J Ciesielski
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 9.  Multimodality imaging of the HER-kinase axis in cancer.

Authors:  Weibo Cai; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.